'DEA Calls For Massive Increases In Psilocybin, Ibogaine And THC Manufacturing This Year To Meet Research Demands' - Marijuana Moment
Portfolio Pulse from Benzinga Newsdesk
The DEA is proposing significant increases in production quotas for marijuana compounds and psychedelics like psilocybin and ibogaine to support research and clinical trials. This move reflects growing interest in these substances for medical and scientific purposes.
September 23, 2024 | 5:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The DEA's proposal to increase psilocybin production quotas could benefit companies like COMPASS Pathways, which focuses on psilocybin research for mental health treatments.
COMPASS Pathways is directly involved in psilocybin research. The DEA's proposal to increase production quotas aligns with the company's focus, potentially facilitating more research and development opportunities.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Cybin Inc., involved in psychedelic research, may benefit from the DEA's increased quotas for psilocybin and other psychedelics, supporting their research initiatives.
Cybin Inc. is engaged in psychedelic research, and the DEA's increased quotas for substances like psilocybin could enhance their ability to conduct studies and develop treatments.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
MindMed, focused on psychedelic research, stands to benefit from the DEA's increased quotas for substances like psilocybin, supporting their clinical trials and research efforts.
MindMed is involved in psychedelic research, and the DEA's increased quotas for psilocybin and other substances could facilitate their clinical trials and research initiatives.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Tilray, a major player in the cannabis industry, might benefit from the DEA's increased THC production quotas, potentially expanding their research and product development.
Tilray is a significant cannabis company, and the DEA's proposal to increase THC production aligns with their business interests, potentially enhancing their research capabilities and product offerings.
CONFIDENCE 85
IMPORTANCE 65
RELEVANCE 75